Antispasmodic Agent
PreclinicalSmall molecule
Antispasmodic Agent is one of 36 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Linzess
AbbVieApproved
Resotran
TakedaApproved
Cymbalta
Jazz PharmaceuticalsApproved
Lexapro
AbbVieApproved
Nurtec
PfizerApproved
Golytely
BayerApproved
Azulfidine
PfizerApproved
Alinia
RRomark Laboratories L.C.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Trental
VValidus Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antispasmodic Agent. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details